Omeprazole (Proton Pump Inhibitor)
Treatment for Peptic Ulcer Disease
Typical Dosage: 20-40mg once daily
Effectiveness
88%
Safety Score
75%
Clinical Trials
19
Participants
500K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
75
DangerousModerateSafe
Treatment Details
Dosage Range
20-40mg once daily
Time to Effect
1-2 weeks for symptom relief, 4-8 weeks for healing
Treatment Duration
4-8 weeks for acute, often longer for maintenance
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
75(Treat 75 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40
Monitoring:$100
Side Effect Mgmt:$20
Total Annual:$160
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$15,000/QALY
QALYs Gained
0.2
Outcome-Based Costs
Cost per Responder
$181.82
Cost per Remission
$205.13
Comparison vs Famotidine (H2RA)
Cost Difference
+$20/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Omeprazole (Proton Pump Inhibitor) Outcomes
for Peptic Ulcer Disease
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+88%
Remission Rate
+78%
Common Side Effects
Headache
+8%
Nausea
+4%
Diarrhea
+4%
Active Clinical Trials
4 active trials recruiting for Omeprazole (Proton Pump Inhibitor) in Peptic Ulcer Disease
OPEN Versus InTact Capsule Proton Pump Inhibitors for the Treatment of Marginal Ulcers
NCT05799105RECRUITINGPHASE4
122 participants
INTERVENTIONAL
Cleveland, United States
Started: Mar 14, 2023
Treatment Efficacy of Regimens With and Without Bismuth in Children With Helicobacter Pylori-Associated Peptic Ulcer Disease
NCT07260006RECRUITINGNA
80 participants
INTERVENTIONAL
Can Tho, Vietnam
Started: Oct 1, 2024
High Dose Oral Omeprazole in High Risk UGIB
NCT04394663RECRUITINGNA
128 participants
INTERVENTIONAL
Pathum Wan, Thailand +1 more
Started: Oct 1, 2020
Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing: A Randomized Controlled Trial
NCT07312370NOT YET RECRUITINGPHASE4
120 participants
INTERVENTIONAL
Lanzhou, China
Started: Jan 20, 2026
Completed Clinical Trials
11 completed trials for Omeprazole (Proton Pump Inhibitor) in Peptic Ulcer Disease
Administration of High-Dose Intravenous Proton Pump Inhibitor for Upper Gastrointestinal Bleeding Prior to Endoscopy
NCT00164866COMPLETEDPHASE4
638 participants
INTERVENTIONAL
Hong Kong SAR, China
Started: Feb 1, 2004
Efficacy of Low Dose of Proton Pump Inhibitor in Treatment Bleeding Ulcers
NCT03163680COMPLETED
295 participants
OBSERVATIONAL
Damascus, Syria
Started: Jan 1, 2012
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
NCT03362281COMPLETEDPHASE3
540 participants
INTERVENTIONAL
Started: Oct 1, 2014
Efficacy of Proton Pump Inhibitor in Prevention of Clopidogrel-related Peptic Ulcer
NCT01138969COMPLETEDPHASE2
165 participants
INTERVENTIONAL
Kaohsiung City, Taiwan
Started: Aug 1, 2008
High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding
NCT00374101COMPLETEDPHASE3
450 participants
INTERVENTIONAL
Polla, Italy +9 more
Started: Jan 1, 2005
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 3)
NCT00952978COMPLETEDPHASE3
496 participants
INTERVENTIONAL
Beijing, China
Started: Sep 1, 2005
Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)
NCT00953381COMPLETEDPHASE2
235 participants
INTERVENTIONAL
Beijing, China
Started: Oct 1, 2004
Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients
NCT02456012COMPLETEDPHASE4
268 participants
INTERVENTIONAL
Tainan, Taiwan
Started: Apr 1, 2015
Efficiency Study of Clarithromycin and Bismuth-containing Quadruple Therapy to Treat H.Pylori
NCT01667575COMPLETEDPHASE4
180 participants
INTERVENTIONAL
Shanghai, China
Started: Aug 1, 2012
The Use of Oral Omeprazole and Intravenous Pantoprazole in Patients With Hypersecretion of Gastric Acid
NCT00001191COMPLETEDPHASE2
INTERVENTIONAL
Bethesda, United States
Started: Feb 3, 1983
Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study
NCT00693225COMPLETEDPHASE4
91 participants
INTERVENTIONAL
Rochester, United States
Started: Jan 1, 2008
Showing 20 of 21 total trials